Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified bivalent COVID-19 vaccine which also targets an Omicron variant.

The company did not disclose which subvariant of Omicron the vaccine would be targetting. (Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)